CINECA IRIS Institutional Research Information System

IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.

AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.

PILERI, Alessandro

Rete di Collaborazioni Statistiche Email Alert RSS Feed

Info

Pubblicazioni (Tutti)

Risultati 1 - 20 di 97 (tempo di esecuzione: 0.001 secondi).

	Titolo	Data di pubblicazione	Autore(i)
11	Trophoblast cell line conditioned medium for in vitro culture and antigenic characterization of acute myeloid leukemia clonogenic cells.	1987	Ferrero D; Pregno P; Tarella C; Ruscetti FW; Pileri A; Gallo E.
12	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter.	1983	CARMAGNOLA AL; BOCCADORO M; MASSAIA M; PILERI A
13	The generation of alloreactive cytotoxic T lymphocytes (CTL) require the expression of ecto-5' nucleotidase activity.	1988	Massaia M; Pileri A; Boccadoro M; Bianchi A; Palumbo A; Dianzani U
14	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.	2000	MAGNI M; DI NICOLA M; DEVIZZI L; MATTEUCCI P; LOMBARDI F; GANDOLA L; RAVAGNANI F; GIARDINI R; DASTOLI G; TARELLA C; PILERI A; BONADONNA G; GIANNI AM
15	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.	2001	MARIANI S; COSCIA M; EVEN J; PEOLA S; FOGLIETTA M; M. BOCCADORO; SBAIZ L; RESTAGNO G; PILERI A; MASSAIA M.
16	Sequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma	1995	Boccadoro M; Palumbo A; Bruno B; Triolo S; Omede P; Argentino C; Pileri A
17	Selection and characterization of early hematopoietic progenitors using an anti-CD71/SO6 immunotoxin.	1994	BENEDETTI G; BONDESAN P; CARACCIOLO D; CHERASCO C; RUGGIERI D; GASTALDI ME; PILERI A; GIANNI AM; C. TARELLA
18	Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.	1993	TARELLA C ;BOCCADORO M ;OMEDÉ P ;BONDESAN P ;CARACCIOLO D ;FRIERI R ;BREGNI M ;SIENA S ;GIANNI AM ;PILERI A
19	Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey	2008	Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A.
20	Retinoic acid inhibits the growth of human myeloma cells in vitro.	1995	Palumbo A; Battaglio S; Napoli P; Bruno B; Omedè P; Boccadoro M; Pileri A
21	Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration.	1993	Bazzan M; Pannocchia A; Tarella C; Stella S; Garbarino G; Pileri A; Tamponi G
22	Recombinant interferon-gamma inhibits the growth of human myeloma cells in vitro.	1994	Palumbo A; Battaglio S; Napoli P; Omedè P; Fusaro A; Bruno B; Boccadoro M; Pileri A
23	Recombinant interferon-gamma in a patient with multiple myeloma.	1994	Palumbo A; Bruno B; Triolo S; Boccadoro M; Pileri A
24	Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.	2002	Ladetto M; Omede P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
25	REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM).	2000	Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Giaccone L; Giaretta F; Volpato F; Bringhen S; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M.
26	REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS	2001	Ladetto M; Omedè P; Sametti S; Donovan JW; Drandi D; Giaccone L; Volpato F; Astolfi M; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
27	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage	2008	Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL)
28	Peripheral blood progenitor cell mobilization in patients with primary refractory lympoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome.	1997	C. TARELLA; CASTELLINO C; CHERASCO C; BONDESAN P; IARETTA F; CORRADINI P; CARACCIOLO D; GAVAROTTI P; PILERI A.
29	Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF.	1991	C. TARELLA; D. FERRERO; M. BREGNI; S. SIENA; E. GALLO; A. PILERI; A.M. GIANNI
30	PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy.	2003	Ladetto M; Drandi D; Volpato F; Astolfi M; Voena C; Compagno M; Novarino A; Pollio B; Addeo A; Ricca I; Falco P; Cavallo F; Vallet S; Corradini P; Pileri A; Tamponi G; Palumbo A; Bertetto O; Boccadoro M; Tarella C

Dettaglio

Nome completo:

PILERI, Alessandro

Varianti:

ARGENTINO C
BONDESAN P
DONOVAN JW
A. PILERI
Alessandro Pileri
ZALLIIO F
CHERASCO C
Pileri A
ZALLIO F
MATTEUCCI P